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Abstract. Analytical ultracentrifugation–sedimentation velocity (AUC-SV) is often used
to quantify high molar mass species (HMMS) present in biopharmaceuticals. Although these
species are often present in trace quantities, they have received signiﬁcant attention due to
their potential immunogenicity. Commonly, AUC-SV data is analyzed as a diffusion-
corrected, sedimentation coefﬁcient distribution, or c(s), using SEDFIT to numerically solve
Lamm-type equations. SEDFIT also utilizes maximum entropy or Tikhonov-Phillips
regularization to further allow the user to determine relevant sample information, including
the number of species present, their sedimentation coefﬁcients, and their relative abundance.
However, this methodology has several, often unstated, limitations, which may impact the
ﬁnal analysis of protein therapeutics. These include regularization-speciﬁc effects, artiﬁcial
Bripple peaks,^ and spurious shifts in the sedimentation coefﬁcients. In this investigation, we
experimentally veriﬁed that an explicit Bayesian approach, as implemented in SEDFIT, can
largely correct for these effects. Clear guidelines on how to implement this technique and
interpret the resulting data, especially for samples containing micro-heterogeneity (e.g.,
differential glycosylation), are also provided. In addition, we demonstrated how the Bayesian
approach can be combined with F statistics to draw more accurate conclusions and rigorously
exclude artifactual peaks. Numerous examples with an antibody and an antibody-drug
conjugate were used to illustrate the strengths and drawbacks of each technique.
KEY WORDS: analytical ultracentrifugation; bayesian analysis; monoclonal antibody; SEDFIT;
sedimentation velocity.
INTRODUCTION
The majority of puriﬁed commercial protein pharmaceu-
tical preparations are accompanied by small quantities of
product-related impurities, including aggregates of the pro-
tein product (1–3). The presence of these aggregates, also
referred to as high molar mass species (HMMS)1 or high
molecular weight species (HMWS), has raised numerous
safety concerns. This is primarily due to the potential
immunogenicity of aggregates larger than dimer (4,5). How-
ever, there are also signiﬁcant difﬁculties in measuring and
predicting various properties of the aggregates, including
concentration, oligomerization state, and stability over a
drug’s shelf life. These concerns are especially pronounced
for monoclonal antibodies, which are often delivered in high-
concentration formulations of >50 mg/ml (6). The enhanced
potential for self-association has resulted in the aggregate
concentration becoming a critical quality parameter during
antibody production, puriﬁcation, and administration.
Size exclusion chromatography–multi-angle light scatter-
ing (SEC-MALS), asymmetric ﬂow ﬁeld-ﬂow fractionation–
multi-angle light scattering (AF4-MALS), and analytical
ultracentrifugation–sedimentation velocity (AUC-SV) are
currently the most common methods for quantifying low
levels of aggregates (2,3,7). However, each of these tech-
niques has its own limitations. For example, SEC-MALS
requires a solid-phase separation matrix, which may interact
with the protein. In addition, it requires sample dilution,
provides limited resolution, and may exclude large aggregates
through a Bsieving effect^ (8,9). AF4 offers resolution over a
limited size range and is generally recognized as being less
robust than SEC-MALS. In addition, the sample is dynami-
cally concentrated and diluted during the separation, which
can alter the number and size of aggregates present (7). In
contrast, AUC is based on ﬁrst principles, with no solid-phase
separation matrix that could interact with the proteins, and
therefore it does not suffer from these same drawbacks (10).
Experiments can be performed in the formulation buffer
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developed for the therapeutics, which is often not optimal for
SEC and AF4 due to frequently encountered protein-matrix
interactions and excipient-membrane interactions, respec-
tively. AUC also has the advantage of separating protein
species over a wider range of hydrodynamic size. In addition,
if a refractive index detector is used to collect data, higher
protein concentrations can be used, which are more repre-
sentative of the therapeutic drug product. The primary
disadvantage of AUC is the expertise required to prepare
samples, perform the experiments, and properly analyze the
data (10,11). However, advances over the last 20 years have
signiﬁcantly improved data analysis and spurred wider use of
AUC for a number of applications (10,12). These include the
characterization of novel pharmaceutical proteins and
biosimilars, from early stage characterization and formulation
development through stability and late-phase comparability
studies (13–19). These applications were made possible by the
emergence of highly advanced data-analysis packages, the
most versatile of which is SEDFIT (17,18,20).
It is outside the scope of this paper to discuss the
mathematical algorithms underlying these programs, which
are detailed elsewhere (15,17,19). Brieﬂy, SEDFIT numeri-
cally ﬁt the ultracentrifugation data to the Lamm equation,
for which an analytical solution does not exist (21). For
velocity experiments (e.g., AUC-SV), the outcome of the
analysis is commonly expressed in terms of a sedimentation
coefﬁcient distribution, c(s). During the experiment, different
species will sediment with speciﬁc rates, measured in Sved-
berg (S) units (1 S= 1 × 10−13 s), depending on their speciﬁc
hydrodynamic properties. Although the c(s) is generally used
for the characterization of protein mixtures, including the
relative abundance of protein species and the detection of
protein–protein interactions, it has several important
limitations. For example, the ﬁtted results associated with a
c(s) are sensitive to the initial ﬁtting parameters, since there is
not an analytical solution to the Lamm equation. The ﬁtted
parameters include the position of the meniscus (22), the type
of noise (23), the resolution (24), the conﬁdence level (25,26),
and the integration range. The use of regularization is also
known to lead to small but systemic errors in the sedimen-
tation coefﬁcients and relative abundance, especially for
species at trace levels (26). In addition, several investigators
have reported variable results depending on the condition of
the hardware, which includes the type and age of cell
centerpieces, windows, and housing (27); the alignment of
cells in the rotor (27); the rotor temperature control (23,28);
and the condition of the rotor itself (16). Nevertheless, if
AUC-SV is performed with due diligence, trace amounts of
HMMS can often be detected and quantiﬁed.
The aim of this work is to re-investigate our ability to use
AUC-SV for detecting and quantifying HMMS in
biopharmaceuticals using the advance tools available in
SEDFIT, including both the explicit Bayesian model and the
F statistics calculator. Speciﬁcally, we address if, and when,
trace oligomeric species present in the normal c(s) are
signiﬁcant and necessary to ﬁt the data. In addition, we
experimentally explore the impact of a Bayesian analysis on
the sedimentation coefﬁcients and relative abundance of
HMMS with a background of a large amount of monomeric
protein. The similarities and differences between the auto-
matic and manual Bayesian tools are also demonstrated.
These analyses can help to answer questions such as when the
results can be trusted, and how to test different hypotheses
regarding the composition of a given sample. To the best of
our knowledge, the combination of Bayesian tools and F
statistics have only been applied to simulated data sets, and
an in-depth discussion of the applications of these tools to
experimental data has not been reported.
MATERIALS AND METHODS
Materials
IgG-ADC, an antibody-drug conjugate, was made by
covalently attaching a small molecule drug to a CHO-
expressed monoclonal IgG4κ antibody. This molecule was
produced and puriﬁed by Pﬁzer Inc. (New York, NY, USA).
Immunoglobulin A (IgA) puriﬁed from human colostrum,
Tris–HCl, and sodium chloride were purchased from Sigma
(St. Louis, MO, USA). Gel ﬁltration Superdex 200 column
was purchased from GE Healthcare Life Sciences (Pittsburgh,
PA, USA). The cell housings and their components used in
the analytical centrifugation experiments were purchased
from Beckman Coulter (Brea, CA, USA).
AUC-SV Experiments
Sedimentation velocity experiments were carried out
using two Beckman Coulter XL-I analytical centrifuges
equipped with absorbance optical systems. Experiments were
performed using either one of the two 4-hole An60 Ti rotors
or the 8-hole An50 Ti rotor. All cells contained sapphire
windows and 12-mm charcoal-ﬁlled Epon double-sector
centerpieces. The following conditions were used in all
sedimentation velocity experiments: 40,000 rpm angular
velocity, 20°C rotor temperature, and 280-nm absorbance
scanned between 5.8 to 7.3 cm radial distances with radial
scanning increment of 0.003 cm. The reference cell contained
420 μl of buffer, and the sample cell contained 410 μl of
protein in the same buffer. After reaching 20°C, the rotor was
equilibrated for an additional hour before starting the
sedimentation run (29). Absorbance data were collected for
each experiment for a minimum of 120 scans and a maximum
of 300 scans.
AUC-SV Data Analysis: Normal c(s)
Sedimentation data analysis was performed using
SEDFIT program version 14.4f (24). All data was initially
analyzed using a continuous distribution, c(s), with maximum
entropy (ME) and Tikhonov-Phillips (TP) regularization. In
all cases, identical values were used to initialize the ﬁtting
parameters: Smin = 0, Smax = 25, buffer density d= 1.00585,
buffer viscosity = 0.01031 P, protein partial speciﬁc volume
= 0.73, frictional ratio = 1.6, and conﬁdence level = 0.7.
However, the reported S values were not corrected for buffer
density and viscosity, as it was unnecessary for the analysis
and did not impact any of the conclusions. The resolution
parameter was set to 251, equivalent to an effective resolution
of 0.1 S, for both the Run and Fit functions of the program.
Values of time-independent noise, meniscus (initial =
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6.02 cm), baseline, and frictional ratio were allowed to ﬂoat
during the ﬁt.
At least 100 scans were used to ﬁt any given data set. For
smaller sets, where the total scan number was less than 130,
every scan was used. For larger data sets, where the number
of scans was greater than 200, every other scan was used. The
ﬁtting limit for data analysis was set approximately 0.02 cm
away from the initial position of the meniscus to avoid any
optical disturbances typically observed at the meniscus. The
position of the upper limit of data analysis was set to fall in
the range of 0.05 to 0.07 cm from the bottom of the cell,
where a plateau was still visible. The experimental data was
ﬁt to generate a c(s) distribution using the Marquardt-
Levenberg global minimization procedure, and the tabulated
c(s) distributions by ME and TP regularizations were
exported to an Excel spreadsheet for peak integration (see
AUC-SV Peak Integration).
AUC-SV Data Analysis: Automatic Bayesian cP(s)
Sedimentation data analysis was ﬁrst performed using
SEDFIT, with all parameters as described above, to generate
a normal c(s). When indicated, the data was modeled with an
automatic Bayesian analysis, cP(s), using only ME
regularization. This was performed using the Ctrl + X
shortcut implemented in SEDFIT (24) and is equivalent to
using the following menu options: Options→Size-Distribution
Options→Prior Knowledge of Discrete Species ^X. This
analysis uses the c(s) as an input and aims to automatically
identify the major species present in the c(s) and ﬁts each
with a delta function (24); i.e., this option informs SEDFIT
that the user has prior knowledge that the sample contains
only discrete species. Following this operation, a distribution
for the sample containing only discrete species at the s values
obtained from the c(s) will appear in SEDFIT as a dotted red
line. Simultaneously, SEDFIT will display the new ﬁt to the
raw data, biased by the assumption of discrete species, as a
solid black line. The resulting peaks in the new distribution,
cP(s), were integrated and analyzed as described in AUC-SV
Peak Integration.
AUC-SV Data Analysis: Manual Bayesian cMP(s)
The manual Bayesian analysis, cMP(s), was performed by
ﬁrst generating a normal c(s), and then by using the Ctrl + W
shortcut implemented in SEDFIT (24). This is equivalent to
using the following menu options: Options→Size-Distribution
Options→Use Prior Probabilities ^W. This option informs
SEDFIT that the user has some degree of knowledge about
the sample, but does not want to incorporate this information
as hard constraints in the ﬁtting. Therefore, the program
incorporates the user-provided information as Bprior
probabilities,^ in contrast to Bprior knowledge^ in automatic
Bayesian operation. In the prior probability operation, the
total number of species used for initialization was manually
varied in a systematic manner, from one to four, to assess the
impact on the analysis. The peak width was initialized to 0.5
for all species to allow for a minimum degree of heterogeneity
within each species, which helps to improve the quality of the
ﬁt based on our experiences. The sedimentation coefﬁcients
and amplitudes were initialized using values obtained from
the initial c(s). Whenever these initial values for the manual
Bayesian were altered, the experimental data was ﬁrst re-ﬁt
to generate a normal c(s). To test the robustness of the
manual Bayesian analysis, several inaccurate seed values
were also used to initialize the cMP(s). These included
artiﬁcial sedimentation coefﬁcients, which differed by at
least 1 S relative to their expected values, as well as
artiﬁcial amplitudes, which differed several-fold from their
expected values. The resulting ﬁts, cMP(s) distributions, were
integrated and analyzed as described in BAUC-SV Data
Analysis: Peak Integration^ section.
AUC-SV Data Analysis: Peak Integration
The calculations of peak areas and weight-average
sedimentation coefﬁcients require an analyst to deﬁne the
peaks of interest. In SEDFIT program, the peak selection is
performed graphically via moving the mouse within a c(s)
proﬁle. This operation carries uncertainties in mouse posi-
tions that impede the reproducibility of the results, even for
repetitive calculations for the same data. When more robust
calculations were desired, the c(s) data were exported to
Excel, and the peak area and weight-average sedimentation
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where h is the resolution of sedimentation coefﬁcient and c(s)i
is the optical density for given sedimentation coefﬁcient, si.
The index parameter, i, is counted from the beginning to the
end of a peak of interest. Excel was used because it permitted
adjustable, numerical peak selection, which allowed for
reproducible comparisons between corresponding peaks
across several different experiments. In addition, one could
examine the data at a later date without having to regenerate
the c(s) ﬁrst by repeating the analysis in SEDFIT. It should be
noted that a similar level of functionality could also be
achieved by using SEDFIT’s option for Bintegration ranges
from a ﬁle.^
AUC-SV Data Analysis: Non-Interacting Discrete Species
Model and F Statistics
All AUC-SV data was ﬁt with the non-interacting
discrete species model in SEDFIT. This model allows for up
to four Bideally sedimenting species^ to be simultaneously ﬁt
to the data (24). All samples were initially ﬁt with models
containing four discrete species. All species-speciﬁc parame-
ters (e.g., c, S, and M) were ﬂoated. The concentration
parameter, (c), for component 1 was initialized to the total
optical density for a given sample (e.g., 1.0) and for
components 2–4, the initial values were relative to that of
component 1 (e.g., 5% of the total optical density would be
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0.05). The molecular weight parameter, (M), and the
sedimentation coefﬁcient parameter, S, were initialized to
the corresponding values obtained from the normal c(s) (e.g.,
∼150 kDa and 5.9 S for component 1). As with the normal
c(s), the meniscus and time-independent (TI) noise parame-
ters were ﬂoated. For each sample, the critical value of root
mean square deviation (RMSD) was determined using the F
statistics calculator in SEDFIT by using the following menu
options: statistics→Calculate variance ratio (F statistics). The
default values were used for the conﬁdence level (0.683), as
well as the ﬁrst and second degrees of freedom. To reduce the
likelihood of the ﬁt being trapped in local minima, both
Marquardt-Levenberg and Simplex global minimization algo-
rithms were used on each data set until there was no change
in the RMSD between two successive ﬁts. Following this, the
Marquardt-Levenberg algorithm was run an additional three
times to ensure the stability of the RMSD. To determine the
signiﬁcance of the minor species in a sample, this ﬁtting
process was systematically repeated using multiple models;
each subsequent model differed from the previous by
removing the least abundant species. In other words, if the
ﬁrst model included the monomer, dimer, and an HMMS, the
second model would only include the monomer and dimer.
Individual species were deﬁned to be statistically signiﬁcant if
their removal from the ﬁt resulted in an RMSD larger than
the critical RMSD.
RESULTS
Impact of the Regularization Methods
One of the fundamental difﬁculties in the algorithm to
generate a sedimentation coefﬁcient distribution, c(s), is that
the process requires an inversion of the Fredholm integral.
This is an ill-posed problem because the solution is not
unique. There are an inﬁnite number of solutions which
describe the data equally well, for any pre-deﬁned threshold
for statistical precision. Furthermore, the subset of solutions
that most optimally ﬁt the data is dominated by high-
frequency oscillations. These often obscure the underlying
information and preclude meaningful interpretation of the
data, especially for trace components. To address this issue,
SEDFIT employs two different types of regularization:
maximum entropy (ME) and Tikhonov-Phillips (TP). Both
are well-established approaches to minimize oscillations in
the solutions to ill-conditioned problems, without signiﬁcantly
impacting the accuracy or precision of the solution.
ME regularization is the default option in SEDFIT (30).
This method biases the solutions toward the subset of
solutions that contain the highest informational entropy (i.e.,
the least information), with the implicit assumption that all
sedimentation coefﬁcients are, a priori, equally likely. This
technique has been recommended by Schuck et al. for
samples containing discrete species (30,31), which is often
the case for pharmaceutical preparations of monoclonal
antibodies (26,32). TP regularization is also available in
SEDFIT, but is based on an alternative set of prior
assumptions. This method biases the solution toward those
that minimize the second derivative of the coefﬁcient
distribution (i.e., those with the least curvature). This
technique is generally recommended for samples that contain
broad or heterogeneous distributions, such as synthetic
polymers or solutions containing heat-stressed aggregates
(30,31). It should be noted that both techniques select the
most parsimonious distribution within a pre-deﬁned conﬁ-
dence level and both are valid. However, differences can arise
in the c(s) proﬁle depending on the regularization method. In
these cases, the assumptions of each approach should be
reviewed.
Figure 1 shows representative c(s) distributions using
ME and TP regularizations for the same IgG-ADC. Although
the integral and sedimentation coefﬁcient of the monomeric
species are similar in both cases, there are signiﬁcant
discrepancies in the dimer and HMMS. In this example, there
are two additional species present in the sample analyzed
with TP regularization. This effect can be seen more clearly in
Table I which tabulates the results of ME and TP
regularizations on the c(s) distribution. For these data, the
results of TP regularization appear to result in a higher
abundance of larger HMMS. However, it is also known that
the ME regularization tends to systematically under-report
HMMS near the detection limit (26). The proper analysis is
important, especially because the presence of higher-mass
aggregates (i.e., larger sedimentation coefﬁcients), and the
relative abundance of aggregates, is thought to be directly
related to immunogenicity of therapeutic proteins. The
solution lies in the proper incorporation of Bayesian prior
probabilities.
Impact of the Automatic Bayesian Analysis
Bayesian tools were incorporated into SEDFIT to
explicitly address some of the aforementioned limitations of
the normal c(s). These include the bias toward the predom-
inant species when using traditional regularization (see
above), as well as the tendency of regularization to generate
artiﬁcial Bripple peaks^ at large s values. In addition, the
Bayesian approach provides a more nuanced method to
incorporate prior knowledge into the c(s) distribution, rather
than relying on the generic, and often unrealistic, assumptions
incorporated into traditional regularization.
The simplest form of an explicit Bayesian analysis within
SEDFIT can be run automatically after ﬁtting AUC-SV data
to a normal c(s) (see BMATERIALS AND METHODS^
section). Figure 2 shows the typical result of the automatic
Bayesian approach, called a cP(s), of an IgG-ADC (i.e., same
sample as shown in Fig. 1). The new distribution is a result of
SEDFIT applying a rational bias to the normal c(s). In other
words, the program generates a second c(s) based on the ﬁrst,
with additional weight being given to the sedimentation
coefﬁcients of the detected species. The most striking
observation is that the choices of regularization no longer
appear to impact the analysis, as the two cP(s) distributions,
based on two c(s) distributions generated by different
regularization methods, are nearly identical. This effect is
more clearly seen in Table II, which tabulates the impact of
the automatic Bayesian approach on the number,
sedimentation coefﬁcient, and percent abundance of all
species. In addition, neither cP(s) contains apparent HMMS
peaks. Rather, the signal originally distributed to these
apparent aggregates has been redistributed across the mAb
monomer and dimer species, as well as a category SEDFIT
852 Wafer et al.
labels as BOTHER MATERIAL.^ The latter does not
necessarily refer to any HMMS and the proper explanation
of this category is addressed in the following paragraph.
Because the interpretation and implications of the new
cP(s) distribution may be very different than those of the
original normal c(s), it is important to emphasize several
caveats of this analysis. First, the automatic Bayesian should
only be applied to data from samples that are known to
contain discrete species. This is because the program forces
all identiﬁed species to have a peak width of 0, by deﬁnition
of the delta function, and may therefore produce erroneous
results for samples that have broad distributions. Figure 3
shows a normal c(s) distribution generated using ME
regularization for a sample containing heterogeneous
aggregates of an IgA antibody, overlaid with its
corresponding cP(s) distribution. The normal c(s) exhibits
three broad peaks centered at ∼11 S, 13.7 S, and 16.5 S.
However, the cP(s) consists of two sharp, discrete peaks and
some broad, artiﬁcial peaks before, between, and after the
two sharp peaks. This non-typical proﬁle indicates the Bprior
knowledge,^ i.e., the underlying assumption of discrete
species applied in the automatic Bayesian, is not applicable
to this sample. Speciﬁcally, peaks at 10.3 S, and 13 S were
generated artiﬁcially by SEDFIT to compensate for the
additional signal that could not be ﬁt to individual, homoge-
neous species. It should also be noted that SEDFIT will
generate a notepad popup window after the automatic
Bayesian is performed, such as that shown in Fig. 3b. Proper
Table I. Comparison of Normal c(s) Distributions for the IgG-ADC Sample Following ME and TP Regularization
ME TP
ADC1 S valuea % Abundancea,b S valuea % Abundancea,b
Monomer 5.98 (0.004) 95.12 (0.37) 5.98 (0.004) 95.30 (0.29)
Dimer 8.87 (0.14) 3.73 (0.47) 8.69 (0.15) 3.18 (0.18)
HMMS 1 12.19 (0.92) 0.77 (0.11) 10.73 (0.17) 0.70 (0.17)
HMMS 2 14.14c 0.11 (0.19) 11.98c 0.21 (0.36)
HMMS 3 n.a. n.a. 13.10 (0.18) 0.27 (0.31)
HMMS 4 n.a. n.a. 14.44 (0.37) 0.22 (0.2)
aThe sedimentation coefﬁcient values are the average of triplicate experiments. The standard deviation is listed after the averaged value in
parentheses
bThe abundance is expressed in terms of integrated signal in the corresponding s value range, relative to the total signal. The standard
deviation is listed after the averaged value in parentheses
cObserved in a single experiment
Fig. 1. Overlaid c(s) distribution proﬁles for the IgG-ADC sample generated using ME
(black) or TP (red) regularizations. The sedimentation coefﬁcient ranges are selected to
show peaks corresponding to the oligomeric species (main panel) or the monomer (inset).
For clarity, the c(s) distribution is arbitrarily scaled relative to the signal of the dimer (main
panel) or monomer (inset). The experimental AUC-SV data was obtained with a rotor
speed of 40,000 rpm, using absorbance detection with 12-mm path length. The initial
sample concentration corresponded to an absorption signal of 0.8 OD12 mm
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care must be taken to correctly interpret this data. For
example, the number of peaks listed within the notepad
popup may be different than the number detected by the user
through visual inspection, or by using the SEDFIT peak
detection algorithm Ctrl + M (see BMATERIALS AND
METHODS^ section). In addition, any signal that SEDFIT
could not ﬁt to the identiﬁed discrete species is placed in a
generic category, labeled as BOTHER MATERIAL.^ It is our
experience that the sedimentation coefﬁcient listed for this
category often corresponds to that of another identiﬁed peak
(e.g., BPeak 2^). However, it is actually a weight-average
value that represents the entire unassigned signal. Therefore,
it could result from both heterogeneity in the identiﬁed
species, as well as the presence of small contaminant species,
which may exist throughout the distribution but are masked
in the cP(s). Furthermore, analysis using F statistics often
demonstrates that the signal assigned to BOTHER
MATERIAL^ is not signiﬁcant. Due to these limitations, we
recommend that the notepad results should be used for
general guidance and not for the ﬁnal interpretation of the
data.
Impact of the Manual Bayesian Analysis
For cases where the automatic Bayesian is not appropri-
ate for the sample (e.g., heterogeneous samples; see Fig. 3), or
additional control of the ﬁtting is desired, a manual Bayesian
analysis can be performed. As with the automatic Bayesian,
this technique should only be used after the AUC-SV data
has already been ﬁt to generate the normal c(s). For this
option, the parameter output associated with the c(s) may
serve as the Bprior probability,^ i.e., initial parameters for the
subsequent Bayesian analysis. Alternatively, the user may
vary the initial parameters to test the sensitivity of the data to
different seed values. Figure 4a shows the result of the
manual Bayesian approach, or cMP(s), applied to the c(s) of
the same IgA sample shown in Fig. 3. Unlike the automatic
Bayesian, which failed to properly ﬁt the broad,
Fig. 2. Overlay of the dimeric (main panel) and monomeric (inset) peaks in the automatic
Bayesian cP(s) distributions performed following the ME (black) or TP regularization (red)
for the same data in Fig. 1. For clarity, the c(s) scale of the main panel is normalized to the
relative abundance of the dimer. The inset shows the unscaled monomer peak, which
perfectly overlaps for both sets of analyses
Table II. Comparison of Automatic Bayesian cP(s) Distribution for the IgG-ADC Sample Following ME and TP Regularization
ME TP
IgG1 s valuea % Abundancea,b s valuea % Abundancea,b
Monomer 5.98 (0.004) 94.77 (0.27) 5.98 (0.004) 94.83 (0.36)
Dimer 8.87 (0.14) 3.60 (0.24) 8.69 (0.15) 3.47 (0.23)
Other materialc 8.87 (0.14) 1.22 (0.37) 8.70 (0.01) 1.70 (0.13)
aReported values are the average of triplicate experiments. The standard deviation is listed after the averaged value in parentheses
bThe integrated signal in the respective integration range relative to the total signal. The standard deviation is listed after the averaged value in
parentheses
cValues obtained from notepad popup and do not necessarily represent HMMS (see text). The standard deviation is listed after the averaged
value in parentheses
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heterogeneous distribution of aggregates, the manual
Bayesian shows an excellent agreement between the cMP(s)
and the prior probabilities (i.e., predicted distribution based
on the results of the initial normal c(s), dashed red line). The
primary beneﬁt of this technique is the ability to test the
sensitivity of the results to various prior probabilities, rather
than simply relying on the general assumptions associated
with conventional regularization. For example, when working
with recombinant biopharmaceuticals, the user often has
information, or reasonable expectations, for the
sedimentation coefﬁcients and relative abundance of the
monomer and dimer. Using this information, one can
determine if the presence of HMMS in the ﬁt depends on
speciﬁc prior probabilities. This is achieved, for example, by
initializing the manual Bayesian analysis with only the
monomeric species or changing the relative abundance of
monomer and HMMS. The manual Bayesian also allows one
to probe the stability of the sedimentation distribution. For
example, one can determine to what extent the ﬁt changes in
response to artiﬁcial, or unreasonable, prior probabilities.
Figure 4b shows a representative example of a cMP(s)
generated using the same IgA data but a false prior
probability. In this example, the sedimentation coefﬁcient
for the dimer peak was initialized at 15 S, rather than the
value observed in the original c(s) (∼13.7 S). Even though
this peak represented a relatively low abundance species,
altering the prior probability had a signiﬁcant impact on the
ﬁt. There is a large deviation from the prior probability
distribution (dashed red line), which was generated using the
initial values (i.e., the prior probability—a species at 15 S). In
addition, the proﬁle of the distribution has changed, creating
a non-symmetrical peak for the affected species and artiﬁ-
cially increasing the sedimentation coefﬁcient for the largest
species.
The difference observed between the cMP(s) and the
prior probability distribution in Fig. 4b provides additional
conﬁdence in the existence of the HMMS at ∼13.7 S, as well
as the sedimentation coefﬁcient determined for this species in
the original analysis. The certainty in ﬁtted sedimentation
coefﬁcients is especially important for large species in low
abundance due to their apparent concentration dependence,
as demonstrated in previous work using simulated AUC-SV
data and the normal c(s) (26,33). If erroneously increased
sedimentation coefﬁcients are not corrected by the manual
Bayesian approach, they may mislead investigators to believe
in the presence of speciﬁc higher-order species. In order to
Fig. 3. a Overlay of the monomeric and HMMS peaks in a normal c(s) (black) and the
corresponding automatic Bayesian cP(s) (red) for the IgA sample. Both proﬁles used ME
regularization. The AUC-SV data was obtained using the same experimental conditions as
Fig. 1. For clarity, the c(s) is shown in the range between 9 and 20 S. The insert shows the
same c(s) and cP(s) at the default scale. b The notepad popup appeared automatically after
the cP(s) analysis for the same IgA sample
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experimentally verify the observations made with the simu-
lated data, we analyzed the apparent sedimentation coefﬁ-
cients of the IgA monomer and dimer using a wide
concentration range.
Figure 5a shows the concentration dependence of the
weight-average sedimentation coefﬁcients for IgA monomer
(∼300 kDa) and dimer (∼600 kDa) in normal c(s) generated
using ME or TP regularization (ﬁlled and open symbols).
Both species exhibited a clear trend of higher sedimentation
coefﬁcients at lower loading concentrations, in agreement
with the simulated data (26,33). Interestingly, the effect is
signiﬁcantly larger when using TP regularization, as com-
pared to ME regularization. At the lowest concentration
tested, the ﬁtted sedimentation coefﬁcient increased by ∼35%
(18.5 S) relative to the expected sedimentation coefﬁcient
(13.7 S). Therefore, the normal c(s) analysis for low-
concentration samples would likely lead to erroneous conclu-
sions regarding the stoichiometries, hydrodynamic radii, and/
or conformational states of the dimer and all HMMS present
in the sample. It is important to note that the artifactual
Fig. 4. a Overlay of the HMMS (main panel) and monomeric (insert) peaks in a manual
Bayesian cMP(s) (black) and the associated prior probability (dashed red line) for the same
IgA data used in Fig. 3. The manual Bayesian analysis was performed following an ME
regularization. For clarity, the cMP(s) is shown at an increased scale in the main panel,
between 12.5 S and 20 S. The insert is independently scaled. b Same overlay as in a, except
that the prior probability (dashed red line) included a false sedimentation coefﬁcient for the
dimer (see BMATERIALS AND METHODS^ section)
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increase in sedimentation coefﬁcient was observed experi-
mentally at concentrations tenfold higher than those pre-
dicted by the simulations (>0.04 OD12 mm vs. 0.004 OD12 mm
or 0.4%, assuming a total load of 1.0 OD12 mm). Furthermore,
this effect was observed for all HMMS components of IgA
(larger HMMS data not shown), which was not predicted by
the simulations.
Figure 5 also shows the impact of performing a manual
Bayesian analysis on the value of sedimentation coefﬁcients.
The solid and the dotted lines indicated that initializing the
sedimentation coefﬁcients with the values obtained in the
preceding normal c(s) ﬁt (i.e., generating prior probabilities)
substantially reduced the spurious increase of the sedimenta-
tion coefﬁcients for the monomer and dimer. At the lowest
loading concentrations, the apparent shift in the sedimenta-
tion coefﬁcient observed for the IgA dimer was ∼2% in the
cMP(s), as opposed to ∼35% in the normal c(s). Similarly, the
cMP(s) exhibited less than a 5% shift in the apparent
sedimentation coefﬁcient for the IgA monomer, whereas the
shift in the same peak in the normal c(s) is ∼10%.
Determining Significance of HMMS Peaks: F Statistics and
Non-Interacting Discrete Species Model
Although the Bayesian analyses offer numerous advan-
tages over the normal c(s), some fundamental questions in
biopharmaceutical application may remain unresolved. For
example, whether a Bripple peak^ with a large sedimentation
coefﬁcient represents an aggregate species, or is simply a
numerical artifact. For samples containing discrete species,
this issue can be addressed using the non-interacting discrete
species model in SEDFIT and the F statistics calculator. The
proper applications of these tools allows the user to conﬁ-
dently determine which species are necessary to properly ﬁt
the data, and are therefore likely to represent real species in
the sample, within a pre-deﬁned conﬁdence interval.
Table III shows representative RMSD values of ﬁtting
IgG-ADC data using the non-interacting discrete species
model, with the step-wise removal of, ﬁrst, HMMS, and then,
both HMMS and dimer. The resulting RMSD values were
compared with the critical RMSD, which was calculated using
the F statistics calculator with the assumption of three
discrete species (monomer, dimer, and HMMS) to determine
the statistical signiﬁcance of the HMMS and the dimer (see
‘MATERIALS AND METHODS^ section). In principle, the
removal of any component decreases the degrees of freedom,
and therefore should increase the RMSD of the ﬁt. However,
when the data was ﬁt with models consisting of only the
monomer and dimer species, the RMSD values were below
the critical RMSD threshold, indicating that the AUC-SV
data can be described equally well with or without the
inclusion of the larger HMMS specie, within the pre-deﬁned
statistical threshold. Therefore, the HMMS resolved in the
original c(s) is not statistically signiﬁcant. On the other hand,
when the dimer and HMMS were removed from the ﬁt, the
RMSD values of the ﬁts were all larger than the critical
RMSD, indicating that the dimer is statistically signiﬁcant and
should be included in the ﬁnal results of the analysis.
Fig. 5. Concentration dependence of the sedimentation coefﬁcients, S, for IgA monomer
(circles) and dimer (triangles) obtained from the normal c(s) with ME (filled symbols) or
TP (open symbols) regularizations. Reﬁned values were obtained by performing the
manual Bayesian, cMP(s), using the values from the normal c(s) by the ME regularization
as the prior probabilities
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As shown in previous sections, there are several caveats
associated with the application of this technique that may
impact the ﬁnal conclusion. The most important among these
is that the discrete species model can only be applied to
samples that consist of non-interacting, discrete species. A
concentration series of AUC-SV experiments, or other
orthogonal techniques, can help to detect dynamic self-
association in a sample, in which case the discrete species
model should not be applied. In addition, one needs to
consider the total number of potentially signiﬁcant, discrete
species present in the sample. SEDFIT limits the total
number of species to four. If more are required, an alternative
data analysis package, such as SEDPHAT (20), should be
used. Furthermore, the non-interacting discrete species model
is sensitive to the ﬂoated parameters for each species:
concentration, mass, and sedimentation coefﬁcient. It is
recommended that these be allowed to ﬂoat in an uncon-
strained manner. However, this may occasionally result in
spurious values, such as mass values that differ from the
expected values by several-fold (e.g., dimer with mass of a
pentamer). This can often be addressed by reﬁtting the data
with a different set of initial values. If the user instead
chooses to constrain a certain parameter, it is critical that the
entire analysis, including the calculation of the critical RMSD,
be performed with the same constraints. Finally, a valid
comparison of the RMSD values requires that the RMSD of
each ﬁt has reached its global minimum. There is no explicit
method to ensure that a global minimum is reached. Users
should rigorously ﬁt the data by, e.g., varying the initial
values, to prevent the analysis from being trapped in local
minima (see BMATERIALS AND METHODS^ section;
AUC-SV Data Analysis).
DISCUSSION
Within the last decade, analytical ultracentrifugation
sedimentation velocity has often been used for characterizing
oligomeric proteins, often in low abundance, in
biopharmaceuticals during their developments. With the
proper sample preparation and data acquisition, users can
reliably obtain signal:noise ratios of 1000:1 and limits of
detection below the RMSD (34). Furthermore, the certainty
in data ﬁtting and the applicability of the incorporated models
have been substantially improved over the last decade.
Surprisingly, these advanced tools to improve the ﬁtting are
absent in numerous experimental studies, especially those
that deﬁne limits of detection and quantitation for AUC-SV
(27,28,33). Consequently, the theoretical gains in accuracy
and precision have not been broadly realized.
In the present work, we provided experimental evidence
for the effectiveness of the Bayesian approach in analyzing
AUC-SV data for biopharmaceuticals. To obtain a c(s)
proﬁle, the software is required to deconvolute the diffusional
broadening that occurs along the monomer-dimer boundary
during sedimentation, which is an ill-posed problem (35).
Although ME and TP regularization can address this issue to
a certain extent, their application requires assumptions that
are demonstrably false: ME assumes that the probability for
all sedimentation coefﬁcients is equally likely, and TP
assumes that the solution with the least curvature is correct.
These assumptions can generate problems that are not
obvious to users, such as the underestimate of dimeric species
and HMMS. In addition, they can lead to artiﬁcial increases
in the values of the sedimentation coefﬁcients for trace
oligomers (26,34). Therefore, even for solutions consisting
of three species, the Bayesian approach offers a beneﬁt in
terms of both the accuracy of the sedimentation coefﬁcients
and the quantitation of HMMS. The use of an explicit
(manual or automatic) Bayesian also allows the incorporation
of sample-speciﬁc information, which is a signiﬁcant advan-
tage over the normal c(s). For example, one can test whether
or not speciﬁc HMMS are necessary to ﬁt the data, by
initializing with only the monomer and/or dimer in setting the
prior probabilities. The result may impact the interpretation
of the experimental data. Similarly, one can test speciﬁc
hypotheses regarding the hydrodynamic properties of indi-
vidual species, including their precise sedimentation coefﬁ-
cient or relative heterogeneity, which is simply not possible by
performing the normal c(s) alone.
This work also demonstrates the application of the F
statistics calculator and the non-interacting discrete species
model to experimental data. For well-behaved samples, these
tools are invaluable for discerning which minor peak(s), if
any, are necessary to ﬁt the data. This may have signiﬁcant
implications for therapeutic antibodies because previously
reported LOD and LOQ were based on analyses using only
the normal c(s). Furthermore, the majority of these studies
used spiked samples consisting of heterogeneous, heat-
stressed aggregates (2,36,37). Such samples are not necessar-
ily representative of process-induced aggregation and may
not be amenable to proper deconvolution using standard
regularization methods, as the heated samples tend to be
highly heterogeneous and exhibit non-discrete proﬁles.
In order to properly address the quantitation of HMMS, we
propose a workﬂow that combines the advantages of the Bayesian
Table III. Determination of Statistical Signiﬁcance for Species Resolved in the IgG-ADC Sample Using the F Statistics Calculator and the
Non-Interacting Discrete Species Model
RMSD
IgG-ADC Critical valuea Monomer + Dimer + HMMSb Monomer + Dimerb Monomerb
Cell 1 0.006805 0.006790 0.006803 0.007903
Cell 2 0.007001 0.006983 0.006996 0.008165
Cell 3 0.006889 0.006871 0.006878 0.007879
aCalculated using the default conﬁdence level and degrees of freedom for a model including the monomer, dimer, and HMMS
bValues correspond to the RMSD for a model using only the listed species
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approaches and F statistics (Fig. 6). Begin with a normal c(s) and
perform the automatic Bayesian in the second step to quickly
determine whether the sample can be ﬁt with a model of discrete
species (e.g., Fig. 2: IgG-ADC) orwhether it requires amodel with
non-discrete species (e.g., Fig. 3: IgA). If the automatic Bayesian
analysis indicates the sample contains only discrete species, the
statistical signiﬁcance of any high s value peaks can be precisely
evaluated using the F statistics calculator and the non-interacting
discrete species model (e.g., Table III). However, if the automatic
Bayesian analysis indicates the sample is heterogeneous with non-
discrete species, themanual Bayesian approach should be utilized.
This procedure allows speciﬁc hypotheses regarding theHMMS to
be explored; Fig. 4 provides an example.
Once the ﬁnal number of species has been determined, the
user can manually integrate the peaks present in the cP(s) or
cMP(s) for the analyzed sample. We believe this approach
addresses numerous deﬁciencies in current practices for
detecting, quantifying, and characterizing oligomers in low
abundance. The application of this integrated approach is
especially beneﬁcial for therapeutic antibodies and antibody-
drug conjugates. Finally, it should be noted that the explicit
Bayesian techniques and the F statistics implemented in SEDFIT
cannot overcome the contribution of experimental error to the
LOD or LOQ of AUC-SV (2,33,37). These approaches can only
reduce the error from the numerical treatment in SEDFIT.
CONCLUSIONS
In the present work, we systematically evaluated the
beneﬁts of performing automatic and manual Bayesian
analyses, as well as F statistics, following the normal c(s)
analysis. We conﬁrmed, with experimental data, that the
combination of the automatic and manual Bayesian analyses
are powerful tools to determine if a sample is signiﬁcantly
heterogeneous or contains discrete species. Furthermore, we
conﬁrmed that these tools correct for the artiﬁcial increase in
sedimentation coefﬁcients of low abundance species, which
has been observed in the normal c(s). For samples consisting
of multiple discrete species in low abundance, F statistics can
be applied to rigorously determine their signiﬁcance. Apply-
ing these tools in the correct manner can signiﬁcantly improve
our capability to detect and quantify aggregates in
biopharmaceuticals using AUC-SV. A coherent strategy for
such an application is demonstrated.
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